Ivan is an accomplished scientific leader with extensive experience at the intersection of biomedical research and commercial innovation. He holds a PhD from Monash University's Australian Regenerative Medicine Institute, following a First-Class Honours degree in Medical Bioscience.

With a career spanning Europe and Asia, Ivan has led international teams, developed new business territories, and built partnerships with CRO and pharmaceutical organisations. His combination of scientific expertise and commercial strategy will support Cyagen's continued expansion and success across global markets.

Benjamin Qu received both his Bachelor’s and Master’s degrees in Biochemistry and Molecular Biology from Nanjing University. In 2013, he moved to the University of Heidelberg, where he earned his Doctor of Philosophy (Dr.rer.nat.) in Biology. Since 2020, he has been a postdoctoral researcher at the Paul-Ehrlich-Institut. He currently serves as Business Development Manager, Southern Europe & Scandinavia at Cyagen.

With over a decade of experience, Benjamin has specialized in viruses, vaccines, and virus/vaccine-induced immunity. He has extensive hands-on expertise with preclinical models, including ESC/iPSC-differentiated cells, primary cells, and genetically modified mice. He has led teams of graduate students and research assistants, and collaborated with cross-functional groups across academia and industry to successfully advance projects.

Delaine is a scientist-turned business development leader with a strong background in metabolism, circadian biology, and cancer research. She completed a B.A. in Biology at the University of Puerto Rico before earning her Ph.D. in Biochemistry from the University of Pennsylvania. She then transitioned from academic research into a commercial role, supporting therapeutic innovation.

Her expertise spans diverse modalities—antibodies, small molecules, ADCs, CAR-T, mRNA, siRNA, peptides, oligonucleotides, AAV, and gene editing—across oncology, immunology, cardiovascular, neuroscience, and ophthalmology.

She now leverages her scientific training and strategic approach to connect researchers—from academic groups to global pharmaceutical teams—with solutions that accelerate discovery and advance innovation.